Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study have?
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study has 10 citations in the OpenAlex counts ScholarIQ stores.
When was Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study published?
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study has 2021 year in the ScholarIQ index.
What is the open-access status of Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study?
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study has hybrid oa status in the ScholarIQ index.
What is the DOI of Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study?
The DOI for Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study is on the source record.
What is the PMID of Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study?
The PMID for Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study is on the source record.
What is the OpenAlex record for Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study?
The OpenAlex for Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study is on the source record.